Arthur Tzianabos, Ph.D.

Dr. Arthur Tzianabos is CEO of Lifordi Immunotherapeutics and a venture partner at 5AM Ventures. He was previously CEO and later Chair of the Board of Directors at Homology Medicines, where he led the company from inception through a successful public offering. While at Homology, Arthur led efforts to develop genetic medicines by leveraging its in vivo gene therapy and nuclease-free gene editing platform for patients with rare genetic diseases. Arthur currently serves on the Board of Directors of Q32 Bio following its merger with Homology earlier this year. He was formerly Chair of the Board of Directors of Akouos, a publicly traded gene therapy company acquired by Lilly in 2022. Prior to this, Arthur spent nine years at Shire, where he worked on the development and launches of multiple treatments for patients with rare genetic disorders and worked closely with the business development team to build Shire’s product pipeline through investments and acquisitions.
 

Earlier in his career, Arthur was a principal investigator and faculty member at Harvard Medical School for 15 years, reaching the rank of associate professor of medicine and maintaining laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He has published more than 80 scientific papers, reviews, book chapters and patents. He holds a B.S. in biology from Boston College and a Ph.D. in microbiology from the University of New Hampshire.